Zhī tōng cái jīng APP learned that Canneso-B (02162) is now up more than 5%, as of press time, up 5.61%, reporting HKD 34.85, with a turnover of HKD 8.6435 million.
In terms of news, Canneso announced that Zhang Lei's team from the Institute of Hematology of the Chinese Academy of Medical Sciences recently published a research paper entitled "A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia" in the New England Journal of Medicine. This is a study initiated by the researchers, a single-arm, open, exploratory clinical study, aimed at evaluating the safety and preliminary efficacy of CM313 in treating adult primary immune thrombocytopenia patients.
A total of 22 patients were enrolled in the study, and all 21 patients other than one who dropped out after the first dose completed 8 doses and 16 weeks of follow-up. In conclusion, CM313 exhibited a rapid and sustained therapeutic response in 95.5% of patients with primary immune thrombocytopenia who received various therapies in the past. Safety analysis showed that CM313 exhibited good safety.